Stoke Therapeutics Inc (OQ:STOK)
Business Focus: Biotechnology & Medical Research
Apr 17, 2024 08:00 am ET
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt has more than 20 years of experience successfully planni
Apr 04, 2024 04:30 pm ET
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 10:15 a
Mar 27, 2024 11:40 pm ET
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the pricing of its upsized underwritten public offering of 5,555,557 shares of its common stock at a price to the public of $13.50 per share and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to an aggregate of 3,703,730 shares of its common stock at a price to the public of $13.4999. The gross proceeds from this offering are expected to be $125 mill
Mar 26, 2024 04:07 pm ET
Stoke Therapeutics Announces Proposed Public Offering
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75 million of shares of its common stock. In addition, Stoke intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares of common stock are being offered by Stok
Mar 25, 2024 04:01 pm ET
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced landmark new data from two open-label Phase 1/2a studies and two open-label extension (OLE) studies of children and adolescent
Mar 25, 2024 04:01 pm ET
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the full year ended December 31, 2023.
Jan 17, 2024 04:30 pm ET
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that, effective on January 16, 2024, the company granted stock options to purchase an aggregate of 13,300 shares of common sto
Jan 08, 2024 08:00 am ET
Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced strategic priorities and anticipated milestones for 2024.
Jan 04, 2024 04:30 pm ET
Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 6:45 p.m.
Dec 01, 2023 09:00 am ET
Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from presentations of clinical data at the American Epilepsy Society (AES) 2023 Annual Meeting December 1 – 5, in O
Nov 21, 2023 08:00 am ET
Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that presentations related to the Company’s work in Dravet syndrome will be presented at the American Epilepsy Society (AES) 2
Nov 11, 2023 07:46 am ET
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Stoke Therapeutics, Inc. (NASDAQ: STOK) and Encourages Investors to Contact the Firm
Kaskela Law LLC announces that it is investigating Stoke Therapeutics, Inc. (NASDAQ: STOK) (“Stoke”) on behalf of the company’s investors. Since July 2023, shares of Stoke’s common stock have declined in value from a trading price of over $10.00...
Nov 07, 2023 07:00 am ET
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the third quarter of 2023 and provided business updates including those related to STK-001, the Company’s
Nov 04, 2023 05:30 am ET
Investor Alert: Abbott Cooper PLLC Announces Investigation into Stoke Therapeutics, Inc.; Urges Stoke Stockholders to Contact Abbott Cooper Regarding Their Legal Rights
Abbott Cooper PLLC is investigating Stoke Therapeutics, Inc. (NASDAQ: STOK) (“Stoke” or the “Company”) on behalf of the Company’s investors. The subject of this investigation is to determine whether Stoke’s board of directors (the “Board”)...
Oct 17, 2023 04:30 pm ET
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that, effective on October 16th, 2023, the company granted a stock option to purchase an aggregate of 32,800 shares of common
Sep 21, 2023 08:00 am ET
Stoke Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will participate in a panel presentation at the 2023 Cantor Global Healthcare Conference on Tuesday, September
Sep 20, 2023 04:30 pm ET
Stoke Therapeutics Appoints Ian Smith to its Board of Directors
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Ian Smith to its Board of Directors effective September 19.
Sep 05, 2023 07:00 am ET
Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from presentations related to the ongoing clinical development of STK-001, the first potential new medicine to trea
Aug 07, 2023 07:00 am ET
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the second quarter of 2023 and provided business updates including those related to STK-001, the company’
Aug 02, 2023 08:00 am ET
Stoke Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023, at 4:30 p.m.
Jul 25, 2023 07:00 am ET
Stoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study i
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced positive new safety and efficacy data from patients treated with STK-001 in the two ongoing Phase 1/2a studies (MONARCH and AD
Jul 21, 2023 07:30 am ET
Stoke Therapeutics to Host Webinar to Present New Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will hold a webinar and conference call for analysts and investors at 8:00 a.m. Eastern Time on Tuesday, July
Jun 16, 2023 04:30 pm ET
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that, effective on June 15, 2023, the company granted stock options to purchase an aggregate of 26,900 shares of common stock
May 04, 2023 07:00 am ET
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the first quarter of 2023 and provided business updates including those related to STK-001, the company’s
May 03, 2023 08:00 am ET
Stoke Therapeutics to Present at the BofA Securities Health Care Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the BofA Securities Health Care Conference on Thursday, May 11, 2023, at 11:00 a.m. ET. (8:00
Apr 25, 2023 07:00 am ET
Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced authorization of its Clinical Trial Application (CTA) by the United Kingdom Medicines and Healthcare products Regulatory Agenc
Mar 15, 2023 07:00 am ET
Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that the FDA will allow the administration of a higher single dose of STK-001 (70mg) in its ongoing Phase 1/2a MONARCH study o
Mar 06, 2023 07:00 am ET
Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the full year ended December 31, 2022 and provided business updates.
Feb 27, 2023 04:30 pm ET
Stoke Therapeutics to Participate at Upcoming March Investor Conferences
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will be participating at the following upcoming investor conferences:
Feb 07, 2023 08:00 am ET
Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 4:20
Jan 09, 2023 08:00 am ET
Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today outlined its expected milestones and the following strategic priorities for 2023:
Jan 04, 2023 08:00 am ET
Stoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 2:15 p.m. E
Dec 02, 2022 09:00 am ET
Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Soc
“Dravet syndrome is a complex and devastating disease that presents challenges for clinicians, patients and their caregivers,” said Barry Ticho, Ph.D., M.D., Chief Medical Officer of Stoke Therapeutics. “To curb the seizures, patients typically take multiple anti-seizure medicines which often produce additional challenges and side effects that impact their quality of life and overall health. STK-001 represents an entirely new approach to treatment, one that aims to treat the syndrome, not just the seizures. At the highest dose level, we observed a 55% median reduction in convulsive seizure fre
Nov 29, 2022 07:30 am ET
Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that seven abstracts related to the Company’s work in Dravet syndrome have been accepted for presentation at the Americ
Nov 14, 2022 07:00 am ET
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the third quarter of 2022 and provided business updates, including positive data from a planned interim a
Nov 10, 2022 07:30 am ET
Stoke Therapeutics to Host Webinar and Conference Call to Present Interim Data from the Phase 1/2a Studies of STK-001 in Children and Adolescents with Dravet Syndrome
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will hold a webinar and conference call for analysts and investors at 8:30 a.m. Eastern Time on Monday, Novemb
Oct 18, 2022 11:16 am ET
Moore Kuehn, PLLC Encourages Investors of Stoke Therapeutics, Inc. to Contact Law Firm
NEW YORK, Oct. 18, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street , is investigating whether certain officers and directors of Stoke Therapeutics, Inc. (NASDAQ: STOK) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
Aug 25, 2022 07:30 am ET
Stoke Therapeutics Enrolls First Patient in a Natural History Study of People Living with Autosomal Dominant Optic Atrophy (ADOA)
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced enrollment of the first patient in a prospective natural history study of people ages 8 to 60 who are living with autosomal do
Aug 08, 2022 07:00 am ET
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the second quarter of 2022 and provided business updates.
Jun 01, 2022 07:30 am ET
Stoke Therapeutics to Present at the 2022 Jefferies Healthcare Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 2022 Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 4:00 p.m. ET.
May 10, 2022 07:00 am ET
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the first quarter of 2022 and provided business updates.
May 02, 2022 04:35 pm ET
Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced new preclinical data that demonstrated dose-related target engagement and increases in OPA1 protein levels in retinal tissue o
Apr 07, 2022 07:30 am ET
Stoke Therapeutics to Present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, announced today the upcoming presentation of new preclinical data on STK-002 at The Association for Research in Vision and Ophthalmology (ARVO
Apr 05, 2022 07:30 am ET
Stoke Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022, at 8:00 a.m.
Mar 10, 2022 07:00 am ET
Stoke Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the full year ended December 31, 2021 and provided business updates.
Feb 28, 2022 07:30 am ET
Stoke Therapeutics to Participate in the Cowen 42nd Annual Health Care Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will participate on the Orphan Neuro Panel at the Cowen 42nd Annual Health Care Conference on Monday, March 7,
Jan 10, 2022 07:00 am ET
Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Stoke Therapeutics, Inc.
Jan 04, 2022 07:30 am ET
Stoke Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 4:30 p.m. ET
Dec 03, 2021 10:00 am ET
Stoke Therapeutics Presents Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2021 Annual Meeting
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from five presentations related to the ongoing clinical development of STK-001 being made at the American Epilepsy
Nov 19, 2021 11:54 am ET
Stoke Therapeutics Announces Presentations from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2021 Annual Meeting
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that five abstracts related to the Company’s work in Dravet syndrome will be presented at the American Epilepsy Society (AES)
Nov 08, 2021 07:00 am ET
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the third quarter of 2021 and provided business updates.
Nov 03, 2021 07:30 am ET
Stoke Therapeutics to Present at Upcoming Investor Conferences in November
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at two upcoming investor conferences in November.
Sep 22, 2021 04:30 pm ET
Stoke Therapeutics to Present at the Cantor Global Healthcare Virtual Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief Medical Officer Barry Ticho, M.D., Ph.D., will present at the Cantor Global Healthcare Virtual Conference on Tuesd
Sep 21, 2021 06:59 am ET
Stoke Therapeutics Announces Positive Interim Safety, PK and CSF Exposure Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced positive safety, pharmacokinetic (PK) and cerebrospinal fluid (CSF) exposure data from a planned interim analysis of the multi
Aug 10, 2021 07:00 am ET
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today reported financial results for the second quarter of 2021 and provided business updates.
Aug 03, 2021 08:00 am ET
Stoke Therapeutics to Present at Upcoming Investor Conferences in August
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at two upcoming investor conferences in August.
May 18, 2021 07:30 am ET
Stoke Therapeutics to Present at the UBS Global Healthcare Virtual Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the UBS Global Healthcare Virtual Conference on Monday, Ma
May 10, 2021 07:30 am ET
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today reported financial results for the first quarter of 2021 and provided business updates.
May 04, 2021 08:00 am ET
Stoke Therapeutics Presents New Data That Demonstrate Tango Antisense Oligonucleotides (ASOs) Increase OPA1 Protein Production and Improve Mitochondrial Function in Cells Derived From Patients With Au
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced new preclinical data demonstrating in-vitro protein upregulation and improved mitochondrial function in OPA1 protein-deficien
Mar 30, 2021 07:30 am ET
Stoke Therapeutics Announces MHRA Authorization to Initiate Phase 1/2a Clinical Trial of STK-001 for Dravet Syndrome in the United Kingdom
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced the authorization of its Clinical Trial Application (CTA) by the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2a study (ADMIRAL) of STK-001 for the treatment of Dravet syndrome.
Mar 24, 2021 07:30 am ET
Stoke Therapeutics to Present at Upcoming Investor Conferences
Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at two upcoming investor conferences, which will each be conducted in a fireside chat format:
Mar 09, 2021 07:30 am ET
Stoke Therapeutics Reports Full Year 2020 Financial Results and Provides Business Updates
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today reported financial results for the full year ended December 31, 2020 and provided business updates.
Mar 04, 2021 07:30 am ET
Stoke Therapeutics to Present at the Barclays Global Healthcare Conference
Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the Barclays Global Healthcare Conference on Thursday, March 11, 2021, at 3:35 p.m. ET.
Jan 04, 2021 04:05 pm ET
Stoke Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021, at 4:30 p.m. ET.
Dec 04, 2020 04:05 pm ET
Stoke Therapeutics to Present at the Needham Virtual Epilepsy & Pain – Specialty CNS Therapeutics Conference
Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will participate in a fireside chat at the Needham Virtual Epilepsy & Pain – Specialty Therapeutics Conference on Thursday, December 10, 2020, at 12:45 p.m. ET.
Dec 04, 2020 09:57 am ET
Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced highlights from presentations being made at the American Epilepsy Society (AES) 2020 Virtual Annual Meeting December 4-8, 2020 related to the Company’s work to advance STK-001, the first potential new medicine to target the underlying cause of Dravet syndrome. Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures that usually begin
Nov 25, 2020 07:30 am ET
Stoke Therapeutics Announces Presentations Related to the Company’s Work in Dravet Syndrome at the American Epilepsy Society 2020 Virtual Annual Meeting
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that four abstracts related to the Company’s work in Dravet syndrome have been selected for presentation at the upcoming American Epilepsy Society (AES) 2020 Virtual Annual Meeting, taking place December 4 – 8, 2020. Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures that usually begin within the first year of life. The disease i
Nov 24, 2020 04:01 pm ET
Stoke Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the closing of its underwritten public offering of 2,875,000 shares of its common stock, including 375,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $39.00 per share. The net proceeds from the offering were approximately $105.1 million, after deducting underwriting discounts and commissions and estimated offering expenses.
Nov 19, 2020 07:00 pm ET
Stoke Therapeutics Announces Pricing of $97.5 Million Public Offering
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a price to the public of $39.00 per share. The gross proceeds from this offering are expected to be $97.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Stoke. The offering is expected to close on or about November 24, 2020, subject to the satisfaction of
Nov 18, 2020 04:02 pm ET
Stoke Therapeutics Announces Proposed Public Offering
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to 2,500,000 shares of its common stock. In addition, Stoke intends to grant the underwriters a 30-day option to purchase up to an additional 375,000 shares of common stock. All of the shares of common stock are being offered by Stoke. The offering is subject to market and other
Nov 12, 2020 07:38 am ET
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported financial results for the third quarter of 2020 and provided business updates.
Nov 09, 2020 07:30 am ET
Stoke Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020, at 3:20 p.m. ET.
Nov 02, 2020 07:30 am ET
Stoke Therapeutics to Present at 29th Annual Credit Suisse Virtual Healthcare Conference
Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will participate in a fireside chat at the 29th Annual Credit Suisse Virtual Healthcare Conference on Monday, November 9, 2020, at 10:15 a.m. ET.
Oct 07, 2020 07:00 am ET
Stoke Therapeutics Announces Plans to Move Forward With Dosing of STK-001 in Children and Adolescents in its Ongoing Phase 1/2a MONARCH Study for Dravet Syndrome
Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced plans to move forward with dosing of STK-001 in children and adolescents in its ongoing Phase 1/2a MONARCH study for Dravet syndrome. Following recent interactions with the U.S. Food and Drug Administration (FDA) related to the partial clinical hold on higher dose levels in the MONARCH study, the FDA will allow the Company to add an additional higher dose level to the single ascendin
Sep 09, 2020 07:30 am ET
Stoke Therapeutics to Present at Cantor Virtual Global Healthcare Conference
Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020, at 9:20 a.m. ET.
Aug 26, 2020 02:00 pm ET
Stoke Therapeutics Announces Publication of Preclinical Data on STK-001 in the Journal Science Translational Medicine that Demonstrate Significant Improvements in Survival and Reductions in Seizure Fr
Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the publication of preclinical data from studies of STK-001 that demonstrated significant improvements in survival and reductions in seizure frequency in a mouse model of Dravet syndrome. Data published today in the journal Science Translational Medicine also showed that STK-001 achieved target engagement, pharmacologic activity and efficacy by selectively increasing Scn1a gene and Na
Aug 17, 2020 07:30 am ET
Stoke Therapeutics Announces Appointment of Garry E. Menzel, Ph.D., to its Board of Directors
Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the appointment of Garry E. Menzel, Ph.D., to both its Board of Directors and Compensation Committee.
Aug 10, 2020 07:30 am ET
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
“Today we are announcing that the first patient has been dosed with STK-001, which we believe has the potential to be the first-disease modifying medicine for Dravet syndrome, a severe and progressive genetic epilepsy that is characterized by developmental delays and cognitive impairment, in addition to seizure activity,” said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. “The start of MONARCH also marks Stoke’s official transition to a clinical-stage biotech company. We enter this new stage in a strong financial position to execute on our plans for STK-001 in Dravet syn
Aug 04, 2020 07:30 am ET
Stoke Therapeutics to Present at Upcoming Investor Conferences in August
Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that members of management will present at three upcoming investor conferences in August:
Jul 09, 2020 05:40 am ET
Stoke Therapeutics Announces Publication of Data in the Journal Nature Communications That Support the Company’s Proprietary Approach to Addressing Severe Genetic Diseases by Precisely Upregulating Pr
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases, today announced the publication of data in the journal Nature Communications that support the company’s proprietary approach to precisely upregulate protein expression using TANGO (Targeted Augmentation of Nuclear Gene Output) antisense oligonucleotides (ASOs).
Jun 04, 2020 08:00 am ET
Stoke Therapeutics Appoints Julie Anne Smith to its Board of Directors
Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the appointment of Julie Anne Smith to its Board of Directors. Ms. Smith has also been appointed to the Compensation Committee of the Board of Directors. Ms. Smith will replace Samuel Hall, Ph.D., whose term on the Board of Directors expired.
May 15, 2020 07:00 am ET
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported financial results for the first quarter of 2020 and provided business updates.
May 12, 2020 08:00 am ET
Stoke Therapeutics Presents Preclinical Data That Demonstrate In-Vitro and In-Vivo Target Engagement and Protein Upregulation in OPA1 Protein Deficiency, the Primary Cause of the Most Common Inherited
Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced new preclinical data demonstrating in-vitro and in-vivo target engagement and protein upregulation in OPA1 protein-deficient cells. OPA1 protein deficiency is the primary cause of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. This is the first proof-of-concept data for TANGO antisense oligonucleotides (ASOs) in an ocular disease. The results
Mar 23, 2020 08:00 am ET
Stoke Therapeutics Reports Full Year 2019 Financial Results and Provides Business Updates
Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported financial results for the full year ended December 31, 2019, and provided business updates.
Feb 24, 2020 08:00 am ET
Stoke Therapeutics to Present at 40th Annual Cowen Health Care Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the 40th Annual Cowen Health Care Conference on Monday, March 2, 2020 at 3:30 p.m. ET in Boston.
Jan 07, 2020 08:30 am ET
Stoke Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company
pioneering a new way to treat the underlying cause of severe genetic
diseases by precisely upregulating protein expression, today
announced that Chief Executive Officer Edward M. Kaye, M.D., will
present at the 38th Annual J.P. Morgan Healthcare Conference
on Tuesday, January 14, 2020 at 2:30 p.m. PT (5:30 p.m. ET) in San
Francisco.
Dec 23, 2019 08:30 am ET
Stoke Therapeutics Added to NASDAQ Biotechnology Index
Stoke Therapeutics, Inc. (Nasdaq:STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI). This addition is effective prior to market open today.
Dec 08, 2019 10:00 am ET
Stoke Therapeutics Presents Preclinical Data on the Biodistribution, Target Engagement and Safety of STK-001 in Non-Human Primates That Support the Planned Clinical Development of STK-001 for the Trea
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today presented new preclinical data on STK-001, a potential new disease-modifying medicine for the treatment of Dravet syndrome. Data from studies in non-human primates (NHP) showed STK-001 distributed throughout the brain and achieved target engagement and increased Nav1.1 protein expression throughout the cortex after a single intrathecal injection. Safety findings showed STK-001 to be well-tol
Dec 07, 2019 12:00 pm ET
Stoke Therapeutics Presents Preclinical Data From Studies of STK-001 That Showed Improvements in Survival and Reductions in Seizure Frequency in a Mouse Model of Dravet Syndrome
Stoke Therapeutics, Inc. (Nasdaq:STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced preclinical data from studies of STK-001 that showed significant improvements in survival and reductions in seizure frequency in a mouse model of Dravet syndrome (DS). New data from electroencephalography (EEG) recordings showed 76% (16/21) of DS mice treated with STK-001 were seizure free compared to 48% (10/21) that were treated with a placebo. An 80% reduction in the average number of spont
Nov 26, 2019 08:30 am ET
Stoke Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the Piper Jaffray 31st Annual Healthcare Conference on Wednesday, December 4, 2019 at 11:50 a.m. ET in New York, NY.
Nov 25, 2019 11:00 am ET
Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that it will present new preclinical data on STK-001, a potential new disease-modifying medicine for the treatment of Dravet syndrome, at the American Epilepsy Society (AES) Annual Meeting, taking place December 6-10, 2019 in Baltimore.
Nov 12, 2019 08:00 am ET
Stoke Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported financial results for the third quarter of 2019.
Nov 05, 2019 08:30 am ET
Stoke Therapeutics to Present at Upcoming Investor Conferences in November
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at two investor conferences in November:
Oct 16, 2019 08:30 am ET
Stoke Therapeutics Strengthens Leadership Team With Appointments of Robin A. Walker, J.D., as Senior Vice President, Chief Legal Officer and Joan Wood as Head of Human Resources
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced the appointments of Robin A. Walker, J.D., as Senior Vice President and Chief Legal Officer, and Joan Wood as Head of Human Resources.
Sep 30, 2019 08:30 am ET
Stoke Therapeutics to Present at 2019 Cantor Global Healthcare Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019 at 10:05 a.m. Eastern time in New York, New York.
Sep 11, 2019 08:00 am ET
Stoke Therapeutics Added to Russell 2000 and 3000 Indexes
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that it has been added to the Russell 2000® and 3000® indexes effective September 20, 2019. Stoke’s addition is based on FTSE Russell’s quarterly update.
Aug 20, 2019 08:00 am ET
Stoke Therapeutics Enrolls First Patient in an Observational Study of Children and Adolescents Living with Dravet Syndrome
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company that is pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced enrollment of the first patient in an observational study of children and adolescents ages 2 to 18 with Dravet syndrome. Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures, beginning within the first year of life. The effects of the disease go beyond seizures and often include cognitive regression or developmental stagnat
Aug 14, 2019 08:00 am ET
Stoke Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported financial results for the second quarter of 2019.
Aug 06, 2019 01:39 pm ET
Stoke Therapeutics Granted FDA Orphan Drug Designation for STK-001, an Investigational New Treatment for Dravet Syndrome
Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead product candidate, STK-001, an investigational new treatment for Dravet syndrome.
Aug 01, 2019 08:00 am ET
Stoke Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference
Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will participate in a fireside chat at the Canaccord Genuity 39th Annual Growth Conference on Thursday, August 8, 2019 at 9:00 a.m. ET in Boston, Mass.
Jun 21, 2019 04:01 pm ET
Stoke Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company that is pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the closing of its initial public offering of 9,074,776 shares of its common stock at a price to the public of $18.00 per share, which includes 1,183,666 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock. All of the shares were offered by Stoke. The shares began trading on The Nasdaq Global Select Market on June 19, 2019 under the symbol
Jun 18, 2019 06:45 pm ET
Stoke Therapeutics Announces Pricing of Initial Public Offering
Stoke Therapeutics, Inc., a biotechnology company that is pioneering a
new way to treat the underlying cause of genetic diseases by precisely
upregulating protein expression, today announced the pricing of its
initial public offering of 7,891,110 shares of its common stock at a
price to the public of $18.00 per share. All of the shares are being
offered by Stoke. The shares are expected to begin trading on The Nasdaq
Global Select Market on June 19, 2019 under the symbol “STOK.” The
offering is expected to close on June 21, 2019, subject to cust
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.